创新药迎来利好！ 另外，有报道指出，艾伯维是荣昌生物合作过的药企中市值最大的一家，根据美国《制药经理人》 （Pharm Exec）杂志公布的2025年度《全球制药企业50强》排行榜，艾伯维2024财年的处方药销售数据 高达544.84亿美元，在全球药企中排名第二，与第一名强生的差距仅约2%。 值得注意的是，昨天，中国创新药核心资产——二代IO疗法发生三件大事。一是荣昌生物重磅且超预 期BD落地；二是康方生物/Summit：AK112与美国BLA申报上市；三是三生制药/辉瑞：PF- 08634404/SSGJ-707将于2026年开展五项全球多中心Ⅲ期临床试验。有分析人士认为，二代IO赛道在全 球的竞争力值得看好。 根据荣昌生物公告，1月12日，公司与艾伯维集团控股公司（以下简称"艾伯维"）就RC148——一款新 型靶向PD-1/VEGF的双特异性抗体药物签署独家授权许可协议，本次交易总额最高为56亿美元（折合人 民币390亿元），首付款为6.5亿美元。 受此带动，今天创新药成为市场主角。荣昌生物A股20%涨停，港股创新药ETF上涨超3%。A股创新药 板块上涨超2.7%。诺思格（301333）、普蕊斯（3012 ...

Core Viewpoint - Rongchang Biopharma signed an exclusive licensing agreement with AbbVie for RC148, a novel bispecific antibody targeting PD-1/VEGF, with a total deal value of up to $5.6 billion (approximately 39 billion RMB) and an upfront payment of $650 million [1][3]. Group 1: Licensing Agreement Details - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China, with Rongchang Biopharma eligible for up to $4.95 billion in milestone payments and a double-digit royalty on net sales outside Greater China [3]. - This deal marks a new high for Rongchang Biopharma in terms of both upfront payment and potential total deal value compared to previous licensing agreements since its Hong Kong listing in 2020 [3]. Group 2: Market Impact - Following the announcement, Rongchang Biopharma's A-shares hit a 20% limit up, and the Hong Kong innovative drug ETF rose over 3%, with the A-share innovative drug sector increasing by over 2.7% [1]. - Significant stock price increases were observed in companies like Nossg, Prasis, and Huaren Health [1]. Group 3: Industry Developments - In the same week, five business development (BD) deals were reported in the innovative drug sector, showcasing China's leading position across various technology fields [6]. - Notable events included the collaboration of Kangfang Biopharma with Summit for AK112's BLA submission in the U.S. and the initiation of global Phase III trials for PF-08634404/SSGJ-707 by 3SBio and Pfizer [4]. Group 4: Market Trends and Valuation - Since the peak of the Hong Kong innovative drug index in September 2025, it has retraced 24%, while the U.S. biotech indices have seen gains of 18% to 29% [7]. - Despite not being at historical lows, the valuation of Hong Kong innovative drugs remains attractive compared to global peers, indicating a growing disparity in asset values between U.S. and Chinese innovative drugs [7].

Core Viewpoint - The article highlights a significant development in the innovative drug sector, particularly focusing on the exclusive licensing agreement between Rongchang Biopharma and AbbVie for the dual-specific antibody drug RC148, which is expected to drive market interest and stock performance in the innovative drug space [1][2]. Group 1: Licensing Agreement Details - Rongchang Biopharma signed an exclusive licensing agreement with AbbVie for RC148, a novel dual-specific antibody targeting PD-1/VEGF, with a total transaction value of up to $5.6 billion (approximately 39 billion RMB) [1][2]. - The agreement includes an upfront payment of $650 million, with potential milestone payments of up to $4.95 billion and tiered royalties on net sales outside Greater China [2]. Group 2: Market Impact - Following the announcement, Rongchang Biopharma's A-shares hit a 20% limit-up, and the Hong Kong innovative drug ETF rose over 3%, indicating strong market enthusiasm [1]. - The innovative drug sector saw a general increase, with the A-share innovative drug sector rising over 2.7%, and notable gains in companies like Nossg, Proris, and Huaren Health [1]. Group 3: Recent Developments in Innovative Drugs - The article notes that three significant events occurred in the second-generation IO therapy sector on January 12, including the successful BD deal for Rongchang Biopharma, AK112's BLA submission by Kangfang Biopharma/Summit, and the initiation of five global Phase III clinical trials for PF-08634404/SSGJ-707 by 3SBio/Pfizer [3]. - A total of five BD deals were reported in the innovative drug sector within a week, showcasing China's leading position across various technological fields [5]. Group 4: Market Trends and Valuation - According to Huatai Securities, since reaching a yearly high in September 2025, the Hong Kong innovative drug index has retraced 24%, while the US biotech indices have shown positive growth, indicating a valuation disparity between Chinese and global innovative drug assets [6]. - Despite not being at historical lows, the current valuation of Hong Kong innovative drugs remains attractive compared to global peers [6].

昨天联手大涨的商业航天和AI应用板块，今天上午，两者走势"分道扬镳"。 商业航天板块大幅波动，在早盘的前7分钟，板块持续下跌，中国卫通、航天发展、航天机电等多只人气股直线跌停。10:35之后，商业航天板块迎来修 复，临近上午收盘，板块拉升，跌幅收窄。 AI应用继续上涨，其中，"AI+制药""AI+医疗"方向走势最强。迪安诊断、中文在线、天龙集团等个股大涨。 此外，保险、油气开采、锂矿等板块上涨。截至上午收盘，上证指数下跌0.03%，深证成指下跌0.31%，创业板指下跌0.83%。 医药股大涨 RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物。目前，荣昌生物正在国内开展RC148单药及联合疗法治疗多种晚期恶性实体瘤患 者的临床研究。荣昌生物上午迎来"20CM"涨停。 2025年5月，三生制药与辉瑞达成的授权交易刷新多项行业纪录。这一事件，重塑了市场对国产创新药出海价值的认知。此后，市场迎来一波创新药板块 行情。 此外，消息面上也有催化。一是当地时间1月12日，英伟达与礼来宣布成立首个专注于将人工智能应用于药物研发挑战的联合创新实验室。 今天上午，医药股大涨，医疗服务、生物制品等板块涨幅 ...

Core Viewpoint - Tempus AI has reported strong preliminary performance for 2025, with projected revenue of approximately $1.27 billion, reflecting an 83% year-over-year growth, and an organic growth of about 30% excluding Ambry business [1] Business Segments - The diagnostics segment is expected to generate approximately $955 million in revenue, showing a year-over-year increase of about 111%, driven by a 26% growth in tumor testing volume and a 29% increase in genetic testing volume [3] - The data and applications segment is projected to achieve total revenue of around $316 million, with a year-over-year growth of approximately 31%, primarily fueled by a 38% increase in the Insights (data licensing) business [3] Fourth Quarter Performance - For the fourth quarter, Tempus AI reported revenue of approximately $367 million, representing an 83% year-over-year increase. The diagnostics segment revenue was about $266 million, up 121% year-over-year, attributed to a 29% growth in tumor testing and a 23% increase in genetic testing volume [4] - The data and applications segment revenue reached $100 million, reflecting a 25% year-over-year growth. Excluding the impact of AstraZeneca's warrants in Q4 2024, the Insights business revenue grew by approximately 68% [4] Contract Value - As of December 31, 2025, the total contract value (TCV) reported by the company exceeded $1.1 billion, marking a historical high [5] Client Agreements - Throughout the year, Tempus established data agreements with over 70 clients, including leading pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Merck, AbbVie, Eli Lilly, and Boehringer Ingelheim, as well as biotech firms like Incyte, Syneos Health, Aspera Biomedicines, Inc., and Whitehawk, Inc. [6] Revenue Retention - The company anticipates a net revenue retention rate of approximately 126% for 2025 [7] Management Commentary - The CEO of Tempus, Eric Lefkofsky, stated that the genomic (oncology) product sales in the diagnostics business have accelerated for the third consecutive quarter, reaching the highest growth rate in years. Both core business segments are experiencing accelerated growth, leveraging the inherent financial leverage of the platform, and the company is entering 2026 with strong momentum. Artificial intelligence is expected to act as a catalyst for all products, and the company is optimistic about 2026 [8]

Core Insights - The company is a rare player in the "AI for Science" sector, founded by three MIT physicists in 2015, focusing on quantum physics first-principles computing combined with AI and robotics to provide drug and materials science R&D solutions [1][2] - The company achieved a revenue of RMB 517 million in H1 2025, representing a year-over-year increase of 404%, with a net profit of RMB 83 million, a significant turnaround from a loss of RMB 362 million in the same period last year [1] Drug Discovery Solutions - The drug discovery solutions segment generated revenue of RMB 435 million in H1 2025, a year-over-year increase of 616%, accounting for 84% of total revenue [1] - The company signed a record-breaking collaboration with DoveTree worth HKD 47 billion (USD 5.99 billion), with an initial payment of USD 51 million and potential milestone payments totaling USD 58.9 billion [2] Pipeline Progress - The company’s incubated pipeline, RTX-117, received approval for clinical trials in China and has also been granted orphan drug designation by the FDA, allowing for expedited review and extended market exclusivity [3] - The global market for CMT treatment is projected to grow from USD 1.013 billion in 2024 to USD 11.394 billion by 2035, indicating significant clinical demand and market growth potential [3] Hair Growth Products - The company developed two innovative hair growth products, Remeanagen (XTP-118) and AquaKine (XTP-016), which have received FDA approval and are set to be launched in overseas markets [4] - The global hair loss treatment market is expected to reach USD 5.044 billion by 2025 and expand to USD 6.146 billion by 2033, with over 2.5 billion people affected by hair loss globally [4][5] Intelligent Robotics Solutions - The company established a scalable standardized intelligent robotics wet laboratory, automating over 80% of chemical experiments to enhance data accumulation and AI model iteration [6] - A strategic partnership with JinkoSolar aims to develop a fully closed-loop solar cell manufacturing line, integrating AI decision-making and robotic execution [6] Investment Recommendations and Profit Forecast - Revenue projections for 2025-2027 are RMB 787 million, RMB 998 million, and RMB 1.465 billion, with year-over-year growth rates of 195.3%, 26.8%, and 46.7% respectively [6] - The company is expected to transition from a "0 to 1" phase to a "1 to N" growth stage, with a validated business model and a high growth trajectory [6][7] Recommendation Logic - The company's foundation in quantum physics provides reusable capabilities in drug discovery and chemical raw materials, positioning it as a leader in the AI for Science infrastructure [7] - Collaborations with major pharmaceutical companies are anticipated to enhance R&D success rates and shorten development cycles, leading to stable cash flow contributions [7] - The partnership with JinkoSolar is expected to open broader application spaces in physical and chemical industries, enhancing the company's reputation and experience [7]

Core Viewpoint - Zhongtai Securities maintains a "Buy" rating for HAPO Pharmaceutical-B (02142), highlighting its position as a key provider of innovative antibody technology globally, supported by collaborations with major pharmaceutical companies like AstraZeneca, Otsuka, Pfizer, and BMS by 2025 [1] Group 1: Collaborations with Major Pharmaceutical Companies - The collaboration with AstraZeneca involves a global strategic partnership to develop next-generation multi-specific antibody therapies for various diseases, marking a deepening of their cooperation with the establishment of an innovation lab in Beijing [2] - The partnership with Otsuka Pharmaceutical focuses on advancing the development of BCMAXCD3TCE for autoimmune diseases, showcasing the advantages of HAPO's proprietary Harbour Mice platform [3] - A non-exclusive licensing agreement with Pfizer aims to accelerate preclinical antibody discovery for various potential disease indications, expanding the scope of collaboration beyond previous ADC licensing [4] - The long-term global strategic cooperation with BMS includes a total payment of $90 million, with potential milestone payments of up to $1.035 billion, indicating a significant deepening of ties with multinational corporations [5] Group 2: Business Model and Financial Outlook - The company's unique business model is expected to yield short-term revenue visibility through upfront payments and achievable R&D milestones, enhancing short-term income [6] - Long-term revenue flexibility is anticipated through sales sharing, providing sustainable cash flow as partner products succeed in the market [6] - The profitability inflection point is deemed certain, with licensing revenues expected to improve net profit margins without substantial capital expenditures, indicating a healthy long-term financial structure [6]

Core Viewpoint - The report from Zhongtai Securities maintains a "Buy" rating for Heptares Therapeutics-B (02142), highlighting its position as a key provider of innovative antibody technology globally, with significant collaborations expected by 2025 with major pharmaceutical companies like AstraZeneca, Otsuka, Pfizer, and BMS [1] Group 1: Collaborations with Major Pharmaceutical Companies - The company has established a global strategic partnership with AstraZeneca to co-develop next-generation multi-specific antibody therapies, marking a deepening of their collaboration with the launch of the Heptares-AstraZeneca Innovation Lab in Beijing [2] - A global strategic cooperation was announced with Otsuka Pharmaceutical to advance the development of BCMAXCD3 TCE for autoimmune diseases, showcasing the advantages of Heptares' proprietary Harbour Mice platform [3] - A non-exclusive licensing agreement was signed with Pfizer to accelerate preclinical antibody discovery research, expanding the collaboration scope significantly [4] - A long-term global strategic cooperation and licensing agreement was reached with BMS, which includes a total payment of $90 million and potential milestone payments of up to $1.035 billion [5] Group 2: Business Model and Financial Outlook - The company's unique business model is expected to yield short-term revenue visibility through upfront payments and achievable R&D milestones [6] - Long-term revenue flexibility is anticipated through sales sharing, providing sustainable cash flow as partner products succeed in the market [6] - The profitability inflection point is deemed certain, with licensing revenues expected to improve net profit margins without significant capital expenditures [6]

Core Insights - The article highlights the rapid growth and international recognition of the company, Yingen Biotech, which specializes in ADC (Antibody-Drug Conjugate) drug development since its establishment in 2019 [1] Group 1: Company Overview - Yingen Biotech has developed four leading technology platforms in the ADC field: DITAC (Immunotoxin Antibody Conjugate), DIBAC (Innovative Bispecific Antibody Conjugate), DIMAC (Immunomodulatory Antibody Conjugate), and DUPAC (Unique Payload Antibody Conjugate) [1] - The company has established a competitive ADC pipeline targeting various promising cancer markers, including HER2, B7-H3, HER3, TROP2, and B7-H4, as well as self-immune targets like BDCA2 [1] - Despite being a relatively new company, Yingen Biotech has secured licensing and strategic partnerships with well-known pharmaceutical companies, including BioNTech and GlaxoSmithKline, for several of its ADC pipelines [1] Group 2: Product Highlights - DB-1311 (B7-H3 ADC) shows significant potential in treating various cancers, particularly prostate cancer, and is closely following the clinical progress of Ifinatamab deruxtecan, which is currently in Phase III trials [2] - DB-1303 (HER2 ADC) aims to differentiate itself in the market by targeting both endometrial cancer (EC) and breast cancer (BC), with the potential to become the first HER2 ADC used for both high and low expression EC [2] - The global market for DB-1303 is promising, especially as it is one of the few ADCs progressing to Phase III clinical trials for HER2-Low BC, alongside DS-8201 [2] Group 3: Strategic Collaborations - Yingen Biotech has formed a strategic partnership with BioNTech, positioning itself within the emerging "second-generation IO+ADC" cancer treatment landscape, which is attracting interest from major multinational corporations [3] - The collaboration with BioNTech, which has also partnered with Bristol-Myers Squibb, enhances Yingen Biotech's global clinical development and commercialization capabilities, maximizing the potential value of its ADC pipeline [3]

Core Viewpoint - The logic of industry-themed funds is changing, moving away from a passive "beta" strategy focused on popular sectors, and towards a more active search for "alpha" opportunities within industries as public funds increasingly focus on performance-driven investments by 2026 [1][2]. Group 1: Market Dynamics - The simple strategy of investing in popular sectors for easy gains has ended, with a shift towards showcasing fund managers' stock-picking abilities in an "alpha" market [2]. - The 2025 annual ranking of Hong Kong QDII funds showed that industry allocation was key to the top-performing funds, indicating a transition to a more competitive investment landscape [2]. - The influx of southbound capital into Hong Kong stocks in 2025 has started to influence pricing in popular sectors, but the market is expected to balance between southbound and foreign capital in 2026 [3]. Group 2: Investment Strategy - Fund managers are now less willing to invest based on "stories" and are demanding tangible performance metrics, indicating a shift towards profitability-driven investments [4]. - The 2026 investment landscape will likely see reduced opportunities for broad-based gains across sectors, with a greater emphasis on individual company performance [4]. - The focus will be on companies that can demonstrate real financial performance rather than those that rely solely on narrative-driven growth [6]. Group 3: Sector-Specific Insights - The importance of overseas business development (BD) deals is highlighted, as they serve as a credibility endorsement for domestic innovative drug companies, impacting their valuation [7]. - In the AI sector, while hardware remains a strong investment, concerns about the application side's profitability are emerging, suggesting a need for careful evaluation of cash flow sources [7]. - The investment strategy for 2026 will emphasize a balanced approach, combining growth-oriented investments with high-dividend stocks to manage risk and return effectively [8]. Group 4: Future Outlook - The market is expected to transition from extreme growth to a more balanced strategy, with a focus on sectors that are currently undervalued and have potential for recovery [8]. - Fund managers are advised to explore non-consensus opportunities, particularly in consumer sectors that are at historical low levels of market expectations and institutional holdings [8].